Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 9, 2008, Pages 745-751

  Simen Kapeu, Aline ^a   Kataja, Vesa ^b,c   Yliskoski, Merja ^d   Syrjänen, Kari ^e   Dillner, Joakim ^f   Koskela, Pentti ^a   Paavonen, Jorma ^g   Lehtinen, Matti ^a,h  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

^d JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY OF HELSINKI   (Finland)

^h UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CHLAMYDIA TRACHOMATIS; CIGARETTE SMOKING; CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; VERRUCA VULGARIS; VIRUS CAPSID; VIRUS CELL INTERACTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CAPSID; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SMOKING; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 50549096652     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540801995360     Document Type: Article

References (26)

1. Zur Hausen, H. (2002) Papillomaviruses and cancer: From basic studies to clinical applications. Nature Rev Cancer, 2, pp. 342-350.
2. Koutsky, L. and Harper, DM. (2006) Current findings from prophylactic HPV vaccine trials. Vaccine, 24, p. S114.
3. Auvinen, E., Niemi, M., Malm, C., Zilliacus, R., Trontti, A. Fingerroos, R. et al. (2005) High prevalence of HPV among female students in Finland. Scand J Infect Dis, 37, pp. 873-876.
4. Andersson-Ellstrom, A., Dillner, J., Hagmar, B., Schiller, J., Sapp, M. Forssman, L. et al. (1996) Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis, 23, pp. 234-238.
5. Schiffman, M., Castle, EP, Jeronimo, J., Rodriguez, AC and Wacholder, S. (2007) Human papillomavirus and cervical cancer. Lancet, 370, pp. 890-907.
6. Carter, JJ, Koutsky, LA, Hughes, JP, Kuang Lee, S, Kuypers, J. Kiviat, N. et al. (2000) Comparison of human papillomavirus type 16, 18 and 6 capsid antibody response following incident infection. J Infect Dis, 181, pp. 1911-1919.
7. Wang, ZH, Kjellberg, L., Abdalla, H., Wiklund, F., Ecklund, C. Knekt, P. et al. (2000) Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. JID, 181, pp. 456-462.
8. af Geijersstam, V, Kibur, M., Wang, Z., Koskela, P., Pukkala, E. Schiller, J. et al. (1998) Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis, 177, pp. 1710-1714.
9. International Collaboration of Epidemiological Studies of Cervical Cancer (2006) Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer, 118, pp. 1481-1495.
10. Szarewski, A., Maddox, P., Royston, P., Jarvis, M., Anderson, M. Guillebaud, J. et al. (2001) The effects of stopping smoking on cervical Langerhans'cells and lymphocytes. Br J Obstet Gynecol, 108, pp. 295-303.
11. Kataja, V., Syrjanen, S., Mantyjarvi, R., Yliskoski, M., Saarikoski, S. and Syrjanen, K. (1992) Prognostic factors in cervical human papillomavirus infections. Sex Transm Dis, 19, pp. 154-160.
12. Jarvis, MJ, Tunstall-Pedoe, H., Feyerabend, C., Vesey, C. and Saloojee, Y. (1987) Comparison of test used to distinguish smokers from non-smokers. Am J Public Health, 77, pp. 1435-1438.
13. Feyerabend, C. and Russell, MA. (1990) A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharmacol, 42, pp. 450-452.
14. Knight, GJ, Wylie, P., Holman, MS and Haddow, JE. (1985) Improved 125I radioimmunoassay for cotinine by selective removal of bridge antibodies. Clin Chem, 31, pp. 118-121.
15. Cummings, SR and Richard, RJ. (1988) Optimum cut-off points for biochemical validation of smoking status. Am J Public Health, 78, pp. 574-575.
16. Lehtinen, M., Kaasila, M., Pasanen, K., Toni, P., Palmroth, J. Laukkanen, P. et al. (2006) Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer, 119, pp. 2612-2619.
17. Dillner, J., Kallings, I., Brihmer, C., Sikstrom, B., Koskela, P. Lehtinen, M. et al. (1996) Seropositivies to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis, 173, pp. 1394-1398.
18. Kjellberg, L., Wang, Z., Wiklund, F., Edlund, K., Ängström, T. Lenner, P. et al. (1999) Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study. J Gen Virol, 80, pp. 391-398.
19. Syrjanen, K., Shabalova, I., Petrovichec, N., Kozachenko, V., Zakharova, T. Pajanidi, J. et al. (2007) Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN. Eur J Epidemiol, 22, pp. 723-735.
20. Wiley, DJ, Wiesmeier, E., Masongsong, E., Gylys, K., Koutsky, L., Ferris, DG and and the Proof of Principle Study Investigative Group (2006) Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. Cancer Epidemiol Biomarkers Prev, 15, pp. 915-920.
21. Onda, T., Carter, JJ, Koutsky, LA, Hughes, JP, Lee, S. Kuypers, J. et al. (2003) Characterization of IgA response among women with incident HPV 16 infection. Virology, 312, pp. 213-221.
22. Anderson, P., Perderson, OF, Bach, B. and Bonde, GJ. (1982) Serum antibodies and immunoglobulins in smokers and non-smokers. Cinical Experimental Immunol, 47, pp. 467-473.
23. Pagliusi, SR and Garland, SM. (2007) International standard reagents for HPV detection. Dis Markers, 23, pp. 283-296.
24. Boffeta, P., Clark, S., Shen Min, Gislefoss, R., Peto, R. and Anderson, A. (2006) Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev, 15, pp. 1184-1188.
25. Arcavi, L. and Benowitz, NL. (2004) Cigarette smoking and infection. Arch Intern Med, 164, pp. 2206-2216.
26. Simons, AM, Mugica van Heckenrode, C, Rodriguez, JA, Maitland, N., Anderson, M. Phillips, DH et al. (1995) Demonstration of smoking-related DNA damage in cervical epithelium and correlation with human papillomavirus type 16, using exfoliated cervical cells. British Journal of Cancer, 71, pp. 246-249.